,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-03-29 04:11:00,"Chicago, IL - March 29, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog.",0.017692720517516136,0.008731884881854057,0.9735754132270813,neutral,0.008960835635662079
1,2018-03-29 04:11:00,Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.,0.021041298285126686,0.011407552286982536,0.9675511121749878,neutral,0.00963374599814415
2,2018-03-29 04:11:00,"Stocks recently featured in the blog include Johnson & JohnsonJNJ , IntelINTC , Procter & GamblePG , CaterpillarCAT and HalliburtonHAL .",0.02474650740623474,0.010070470161736012,0.9651829600334167,neutral,0.01467603724449873
3,2018-03-29 04:11:00,"Here are highlights from Wednesday's Analyst Blog:

The Zacks Research Daily presents the best research output of our analyst team.",0.2265114039182663,0.00957189779728651,0.7639166712760925,neutral,0.2169395089149475
4,2018-03-29 04:11:00,"Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Intel and Procter & Gamble.",0.049089934676885605,0.008848382160067558,0.9420616626739502,neutral,0.040241554379463196
5,2018-03-29 04:11:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
6,2018-03-29 04:11:00,"Buy-rated Johnson & Johnson 's shares have lost -2.2% in the last six months, outperforming the -5.4% decline of the Zacks Large Cap Pharmaceuticals industry.",0.018456077203154564,0.9720912575721741,0.009452647529542446,negative,-0.9536351561546326
7,2018-03-29 04:11:00,J&J's sales growth accelerated in the second half of 2017 backed by higher sales in the Pharmaceutical segment and improving performance in Medical Devices.,0.9556300044059753,0.01673651486635208,0.027633490040898323,positive,0.9388934969902039
8,2018-03-29 04:11:00,"Though quite a few key products in J&J's portfolio like Remicade and Concerta are facing generic competition, the Zacks analyst thinks new products in all segments, label expansion of drugs like Imbruvica and Darzalex and contribution from recent acquisitions - mainly Actelion - can support top-line growth.",0.9340416789054871,0.013201777823269367,0.05275649577379227,positive,0.9208399057388306
9,2018-03-29 04:11:00,"Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support.",0.8379889726638794,0.01725011132657528,0.14476092159748077,positive,0.8207388520240784
10,2018-03-29 04:11:00,J&J is also making rapid progress with its pipeline and line extensions.,0.9287897348403931,0.01426844671368599,0.05694182589650154,positive,0.9145212769508362
11,2018-03-29 04:11:00,"However, headwinds like generics, pricing pressure and soft global market conditions remain.",0.03293194994330406,0.9173542857170105,0.049713727086782455,negative,-0.8844223618507385
12,2018-03-29 04:11:00,"Shares of Intel 's shares have outperformed the Zacks General Semiconductor industry over the past six months, gaining +34.4% vs. +27.2%.",0.6909139752388,0.2868128716945648,0.022273121401667595,positive,0.40410110354423523
13,2018-03-29 04:11:00,Intel is the world's largest manufacturer of semiconductor products.,0.34267088770866394,0.00867950078099966,0.6486496329307556,neutral,0.3339913785457611
14,2018-03-29 04:11:00,"The company is benefiting from robust performance of the DCG, IoT Group, NSG and PSG.",0.9523280262947083,0.015903504565358162,0.03176851198077202,positive,0.9364244937896729
15,2018-03-29 04:11:00,These segments form the crux of Intel's data-centric business model.,0.02953232452273369,0.005162399727851152,0.9653052687644958,neutral,0.024369925260543823
16,2018-03-29 04:11:00,"Further, the launch of FPGA SDK for OpenCL solution, Xeon Scalable, Core 8 chips, Myriad X and next-generation desktop processors are key catalysts.",0.7160636782646179,0.01147957518696785,0.2724567651748657,positive,0.7045841217041016
17,2018-03-29 04:11:00,"Lately, Intel's Movidius vision processing has gained strong adoption.",0.935005247592926,0.015729302540421486,0.04926541447639465,positive,0.9192759394645691
18,2018-03-29 04:11:00,The processor was selected by Alphabet's Google division and Amazon.com's DeepLens.,0.19994696974754333,0.007995134219527245,0.7920579314231873,neutral,0.19195184111595154
19,2018-03-29 04:11:00,"Intel's partnerships with BMW, Nissan, Volkswagen AG and Ferrari will boost sales of processing chips, sensor-chips, cloud software and many more, which will drive top-line growth.",0.948479950428009,0.018179066479206085,0.03334099054336548,positive,0.9303008913993835
20,2018-03-29 04:11:00,"However, stiff competition from peers adds to its woes.",0.09372567385435104,0.8693252801895142,0.03694899007678032,negative,-0.7755995988845825
21,2018-03-29 04:11:00,Procter & Gamble 's shares have underperformed the Zacks Soap and Cleaning Materials industry over the last six months (-14.5% vs. -10.6%).,0.15099965035915375,0.8216920495033264,0.02730831876397133,negative,-0.6706923842430115
22,2018-03-29 04:11:00,"The Zacks analyst likes its strong brand recognition, diversified portfolio, impressive product development capabilities and marketing prowess as well as strong cash flow productivity.",0.8973270654678345,0.013060495257377625,0.0896124392747879,positive,0.8842665553092957
23,2018-03-29 04:11:00,"The company remains focused on balanced growth through improved product, packaging, and marketing initiatives and productivity cost-savings plan.",0.8996971249580383,0.012836354784667492,0.08746648579835892,positive,0.8868607878684998
24,2018-03-29 04:11:00,Earnings estimates for fiscal 2018 have moved north over the last 60 days signaling analysts' optimism.,0.8371783494949341,0.06148535758256912,0.10133633762598038,positive,0.7756929993629456
25,2018-03-29 04:11:00,"However, slowing market growth, weak volumes and organic sales have been hurting sales.",0.020871460437774658,0.9673427939414978,0.011785798706114292,negative,-0.9464713335037231
26,2018-03-29 04:11:00,Soft consumer-spending environment in developed markets and uncertainties in emerging countries also add to the worries.,0.09388434886932373,0.5690229535102844,0.33709272742271423,negative,-0.4751386046409607
27,2018-03-29 04:11:00,"That said, P&G is speeding up innovations and investments to counter the softening industry growth.",0.8501840829849243,0.012819827534258366,0.13699613511562347,positive,0.8373642563819885
28,2018-03-29 04:11:00,Other noteworthy reports we are featuring today include Caterpillar and Halliburton.,0.03325582295656204,0.005807188339531422,0.960936963558197,neutral,0.027448635548353195
29,2018-03-29 04:11:00,Will You Make a Fortune on the Shift to Electric Cars?,0.16753385961055756,0.018516888841986656,0.8139492273330688,neutral,0.14901697635650635
30,2018-03-29 04:11:00,Here's another stock idea to consider.,0.05285736173391342,0.007070568855851889,0.9400720596313477,neutral,0.045786794275045395
31,2018-03-29 04:11:00,"Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics.",0.47791752219200134,0.07177354395389557,0.4503089487552643,positive,0.4061439633369446
32,2018-03-29 04:11:00,Soon electric vehicles (EVs) may be cheaper than gas guzzlers.,0.5187358856201172,0.013680092990398407,0.4675840437412262,positive,0.5050557851791382
33,2018-03-29 04:11:00,Some are already reaching 265 miles on a single charge.,0.453574001789093,0.02303212694823742,0.5233939290046692,neutral,0.43054187297821045
34,2018-03-29 04:11:00,"With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.",0.515029788017273,0.07344300299882889,0.41152721643447876,positive,0.44158679246902466
35,2018-03-29 04:11:00,It's not the one you think.,0.04626888781785965,0.042117830365896225,0.9116132855415344,neutral,0.004151057451963425
36,2018-03-29 04:11:00,"Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.",0.01284766010940075,0.009404126554727554,0.9777481555938721,neutral,0.003443533554673195
37,2018-03-29 04:11:00,Past performance is no guarantee of future results.,0.023727279156446457,0.008731111884117126,0.9675416350364685,neutral,0.01499616727232933
38,2018-03-29 04:11:00,Inherent in any investment is the potential for loss .,0.023265572264790535,0.09617827832698822,0.8805561661720276,neutral,-0.07291270792484283
39,2018-03-29 04:11:00,"This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security.",0.011962415650486946,0.010706594213843346,0.9773310422897339,neutral,0.0012558214366436005
40,2018-03-29 04:11:00,No recommendation or advice is being given as to whether any investment is suitable for a particular investor.,0.01822577603161335,0.008984367363154888,0.9727898240089417,neutral,0.009241408668458462
41,2018-03-29 04:11:00,"It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable.",0.020858757197856903,0.007662615738809109,0.9714785814285278,neutral,0.013196141459047794
42,2018-03-29 04:11:00,All information is current as of the date of herein and is subject to change without notice.,0.01124907098710537,0.013303965330123901,0.9754469990730286,neutral,-0.002054894343018532
43,2018-03-29 04:11:00,Any views or opinions expressed may not reflect those of the firm as a whole.,0.008276145905256271,0.021656149998307228,0.9700676798820496,neutral,-0.013380004093050957
44,2018-03-29 04:11:00,"Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities.",0.009504852816462517,0.012596068903803825,0.9778990745544434,neutral,-0.0030912160873413086
45,2018-03-29 04:11:00,These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs.,0.14585068821907043,0.02033580094575882,0.8338135480880737,neutral,0.1255148947238922
46,2018-03-29 04:11:00,These are not the returns of actual portfolios of stocks.,0.010538044385612011,0.012450686655938625,0.9770112633705139,neutral,-0.0019126422703266144
47,2018-03-29 04:11:00,The S&P 500 is an unmanaged index.,0.022511588409543037,0.0801919475197792,0.8972964882850647,neutral,-0.05768036097288132
48,2018-03-29 04:11:00,Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.,0.01104306522756815,0.014137434773147106,0.9748194813728333,neutral,-0.0030943695455789566
49,2018-03-29 04:11:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
50,2018-03-29 04:11:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069374665617943,0.007019795011729002,0.9422864317893982,neutral,0.04367395117878914
51,2018-03-29 04:11:00,"Click to get this free report

To read this article on Zacks.com click here.",0.02068457007408142,0.033159855753183365,0.9461556077003479,neutral,-0.012475285679101944
52,2018-03-29 04:11:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
